Interim data from phase III HAVEN 6 study demonstrate favourable safety and efficacy profile of Roche’s Hemlibra in people with moderate or mild haemophilia A

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

David Linetsky
Point-of-Care Marketing

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice

Paul Theisen
Patient Acquisition